Quick Answer
Prelude Therapeutics Inc reported Revenue From Contract With Customer Excluding Assessed Tax of $12.14 million for the year ending 2025.
- Prelude Therapeutics Inc showed an increase of +73.4% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
- This data is from Prelude Therapeutics Inc's annual report (Form 10-K), filed with the SEC on March 10, 2026.
- XBRL data for this metric is available from 2024 to 2025 (2 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Historical annual values: Fiscal year 2025: $12.14 million | Fiscal year 2024: $7.00 million.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: